I27.21
Secondary pulmonary arterial hypertension
Clinical Classification Guidelines
Inclusion Terms
- (Associated) (drug-induced) (toxin-induced) pulmonary arterial hypertension NOS
- (Associated) (drug-induced) (toxin-induced) (secondary) group 1 pulmonary hypertension
Code Also
- associated conditions if applicable, or adverse effects of drugs or toxins, such as:
- adverse effect of appetite depressants (T50.5X5)
- congenital heart disease (Q20-Q28)
- human immunodeficiency virus [HIV] disease (B20)
- polymyositis (M33.2-)
- portal hypertension (K76.6)
- rheumatoid arthritis (M05.-)
- schistosomiasis (B65.-)
- Sjögren syndrome (M35.0-)
- systemic sclerosis (M34.-)
Medical Intelligence & Overview
Secondary pulmonary arterial hypertension (PAH) is a condition where the blood pressure in the arteries of the lungs becomes abnormally high due to an underlying condition. Unlike primary PAH, which has no identifiable cause, secondary PAH develops as a result of other health issues like certain diseases, medications, or toxins. Recognized under ICD-10 code I27.21, this condition can lead to increased strain on the right side of the heart and may cause serious health complications if not managed properly.
Causes & Symptoms
Clinical Causes: Underlying lung diseases such as chronic obstructive pulmonary disease (COPD) or interstitial lung disease Heart conditions like left heart failure or congenital heart defects Blood clots in the lungs (pulmonary embolism) Chronic injury or inflammation of the lung blood vessels Use of certain medications, such as appetite suppressants or chemotherapy agents Exposure to toxins or chemicals that damage lung tissue or blood vessels Other conditions that cause elevated pressures in the lungs or damage to pulmonary arteries
Key Symptoms: Shortness of breath, especially during physical activity Fatigue and weakness Chest pain or discomfort Palpitations or irregular heartbeat Dizziness or fainting spells Swelling in the ankles, legs, or abdomen Lightheadedness or difficulty breathing when lying down
Diagnostic & Treatment
Diagnosis Path: Diagnosing secondary pulmonary arterial hypertension involves a series of tests to determine the underlying cause and assess lung and heart function. Common diagnostic procedures include: - Echocardiogram to visualize heart and pulmonary artery pressures - Right heart catheterization for accurate measurement of pulmonary arterial pressures - Chest X-ray or CT scan to evaluate lung structure - Pulmonary function tests to assess lung capacity - Blood tests to identify underlying medical conditions - Electrocardiogram (ECG) to monitor heart activity The physician reviews these results collectively to confirm the diagnosis and determine the severity of the condition.
Treatment Protocols: Management of secondary pulmonary arterial hypertension aims to address the underlying cause and alleviate symptoms. Treatment options may include: - Treating underlying lung or heart diseases to reduce pulmonary pressures - Medications such as diuretics for fluid management, oxygen therapy to ensure adequate oxygenation, and vasodilators to widen blood vessels - Using anticoagulants if blood clots are involved - Adjusting or discontinuing medications or toxins that may contribute to PAH - Lifestyle modifications like maintaining a healthy weight, engaging in suitable physical activity, and avoiding exposure to harmful substances - In some cases, advanced interventions such as pulmonary vasodilator therapy or surgery may be considered Close monitoring and regular follow-ups are critical to managing the condition effectively and preventing complications.
Clinical Advice & FAQs
Billing Guidance
Is I27.21 a billable ICD-10 code?
Yes, I27.21 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report I27.21?
Clinical documentation must specify the nature of Secondary pulmonary arterial hypertension and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
